Dr.Aditi Shastri obtained her MBBS degree at the Lokmanya Tilak Municipal Medical College in Mumbai, India and completed her internal medicine residency at the Baylor College of Medicine in Houston, TX followed by a fellowship in Hematology/Oncology at the Montefiore Medical Center & Albert Einstein College of Medicine. She joined the faculty of the Department of Oncology in 2015 and in 2020 received an appointment with the Department of Developmental & Molecular biology. She is now an Associate professor in both departments. Her clinical expertise is in treating patients with myeloid malignancies such as AML and MDS, and treating adult bone marrow failure syndromes. Her lab focuses on therapeutically targeting STAT3 in MDS/AML stem cells as well as projects with large clinical & genomic datasets that have a health equity focus. Dr. Shastri is specifically interested in therapeutics targeting aberrant stem and progenitor cells in MDS and AML. She is developing multiple therapeutics for treating therapy resistant MDS/AML in her lab and clinically as well as on the research front, her focus has expanded to included pre-disease conditions such as clonal hematopoiesis and novel therapeutics targeting CH.
Dr.Shastri’s research has been funded by the NIH, the Leukemia Lymphoma Society, and the MDS Foundation among others.